论文部分内容阅读
目的结合临床案例,对肾性贫血患儿使用重组人促红素-α(EPO-α)治疗无效时治疗方案的调整进行文献检索和分析,为给药方案的优化提供解决途径和新的临床思路。方法报道、分析我院1例案例,同时查阅文献进行讨论分析。结果本例患儿在使用重组人促红素-α治疗无效后,换用重组人促红素-β(EPO-β)持续治疗两个月后,患者贫血症状缓解,贫血程度由重度转为轻度,血红蛋白由60 g·L~(-1)上升至100 g·L~(-1)以上。结论对于重组人促红素-α治疗无效的肾性贫血患儿,可以换用重组人促红素-β改善贫血。
Objective To combine the clinical cases with the literature retrieval and analysis of the adjustment of the treatment regimen in children with renal anemia when using recombinant human erythropoietin-α (EPO-α), so as to provide a solution for the optimization of the dosage regimen and a new clinical Ideas. Methods reported, analysis of 1 case of our hospital, while consulting the literature for discussion and analysis. Results After treatment with recombinant human erythropoietin-α for a period of two months, the patients were relieved of the symptoms of anemia and the degree of anemia was changed from severe to Mild hemoglobin increased from 60 g · L -1 to above 100 g · L -1. Conclusions For children with renal anemia who are refractory to recombinant human erythro-α, recombinant human erythropoietin can be used to improve anemia.